SavedAdd your journal

Journals / Ankara Üniversitesi Eczacılık Fakültesi Dergisi / 2022 / Cilt: 46 - Sayı: 1

CURRENT APPROACHES TO TARGETED THERAPY: LUTETIUM-177 LABELED RADIOPHARMACEUTICALS

HEDEFE YÖNELİK TEDAVİDE GÜNCEL YAKLAŞIMLAR: LUTESYUM-177 İLE İŞARETLİ RADYOFARMASÖTİKLER

Dorukhan HIŞIR
Meliha EKİNCİ
Derya İLEM-ÖZDEMİR
Pages
209–230
Publication Date
2022-01-29
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this review, it is aimed to explain the basic information about radiopharmaceuticals, targeted therapy, theranostics and Lu-177, to present 177Lu-labeled molecular carriers and 177Lu-labeled radiopharmaceuticals and to review the studies on these subjects.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: In recent years, thanks to advances in targeted radionuclide therapy, significant advances have been made in the early diagnosis and treatment of diseases.
📊
Key Findings & Data:With the emergence of the concept of "theranostic", which combines diagnosis and treatment methods, Lutetium-177 (Lu-177) has gained an important place in targeted therapy and has become a leading compound in this field.
💡
Conclusion & Impact:In this review, it is aimed to explain the basic information about radiopharmaceuticals, targeted therapy, theranostics and Lu-177, to present 177Lu-labeled molecular carriers and 177Lu-labeled radiopharmaceuticals and to review the studies on these subjects.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Lutesyum-177 · radyonüklid · radyofarmasötik

Abstract

Objective: In recent years, thanks to advances in targeted radionuclide therapy, significant advances have been made in the early diagnosis and treatment of diseases. With the emergence of the concept of "theranostic", which combines diagnosis and treatment methods, Lutetium-177 (Lu-177) has gained an important place in targeted therapy and has become a leading compound in this field. In this review, it is aimed to explain the basic information about radiopharmaceuticals, targeted therapy, theranostics and Lu-177, to present 177Lu-labeled molecular carriers and 177Lu-labeled radiopharmaceuticals and to review the studies on these subjects.

Özet

Amaç: Son yıllarda, hedefe yönelik radyonüklid tedavisindeki ilerlemeler sayesinde hastalıkların erken teşhis ve tedavisinde önemli gelişmeler kaydedilmiştir. Tanı ve tedavi yöntemlerini birleştiren “teranostik” kavramının doğmasıyla Lutesyum-177 (Lu-177), hedefe yönelik tedavide önemli bir yer edinmiş ve bu alanda öncü bir bileşik haline gelmiştir. Bu derlemede, radyofarmasötikler, hedefe yönelik tedavi, teranostikler ve Lu-177 ile ilgili temel bilgilerin anlatılması, 177Lu ile işaretli moleküler taşıyıcılar ile 177Lu’dan hareketle hazırlanan radyofarmasötiklerin sunulması ve bu konularda yapılmış olan çalışmaların gözden geçirilmesi amaçlanmıştır.

🔖

Cite This Article

HIŞIR, D., EKİNCİ, M., İLEM-ÖZDEMİR, D. (2022). CURRENT APPROACHES TO TARGETED THERAPY: LUTETIUM-177 LABELED RADIOPHARMACEUTICALS. Ankara Üniversitesi Eczacılık Fakültesi Dergisi, Cilt: 46 - Sayı: 1, 209–230. https://ajindex.com/articles/394657

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (4)

  1. Sivri, N.N. (2004). Radyonüklidik tedavi. Meslek İçi Sürekli Eğitim Dergisi, 9–10, 11–17
  2. Ekinci, M., İlem-Özdemir, D. (2021). Radyofarmasötikler ve teranostikler. Journal of Literature Pharmacy Sciences, 10(1), 119–132. [CrossRef] 3. Banerjee, S., Pillai, M.R.A., Knapp, F.F. (2015). Lutetium-177 therapeutic radiopharmaceuticals: Linking chemistry, radiochemistry, and practical applications. Chemical Reviews, 115(8), 2934– 2974. [CrossRef] 4. Riondato, M., Eckelman, W.C. (2016). Radiopharmaceuticals. In: A. Ciarmiello, L. Mansi (Eds.). PET-CT and PET-MRI in Neurology: SWOT Analysis Applied to Hybrid Imaging (pp. 31–57). Springer International Publishing. [CrossRef] 5. Ekinci, M., İlem-Özdemir, D. (2021). İyonlaştırıcı radyasyon ve onkolitik virüsler ile kombine tedavinin etkileri. FABAD Journal of Pharmaceutical Sciences, 46(1), 79–92
  3. Ekinci, M., İlem-Özdemir, D. (2021). Nanoteranostikler. Ankara Üniversitesi Eczacılık Fakültesi Dergisi, 45(1), 131-155 [CrossRef] 7. Nurili, F., Vural, G.U., Aras, Ö. (2015). Molecular imaging methods in theranostic platform. Nuclear Medicine Seminars, 2, 120–127
  4. Ersahin, D., Doddamane, I., Cheng, D. (2011). Targeted radionuclide therapy. Cancers, 3(4), 3838–3855. [CrossRef] 9. Zukotynski, K., Jadvar, H., Capala, J., Fahey, F. (2016). Targeted radionuclide therapy: Practical applications and prospects. Biomarkers in Cancer, 8s2(8), BIC.S31804. [CrossRef] 10. Goldsmith, S.J. (2020). Targeted radionuclide therapy: A historical and personal review. Seminars in Nuclear Medicine, 50(1), 87–97. [CrossRef] 11. Jurcic, J.G., Wong, J.Y.C., Knox, S.J., Wahl, D.R., Rosenblat, T.L., Meredith, R.F. (2016). Targeted radionuclide therapy. In: L.L. Gunderson, J.E. Tepper (Eds.). Clinical Radiation Oncology (Fourth Edition) (pp. 399-418.e14). Elsevier. [CrossRef] 12. Dash, A., Chakraborty, S., Pillai, M.R.A., Knapp, F.F.R. (2015). Peptide receptor radionuclide therapy: An overview. Cancer Biotherapy and Radiopharmaceuticals, 30(2), 47–71. [CrossRef] 13. Dash, A., Pillai, M.R.A., Knapp, F.F. (2015). Production of 177Lu for targeted radionuclide therapy: Available options. Nuclear Medicine and Molecular Imaging, 49(2), 85–107. [CrossRef] 14. Das, T., Banerjee, S. (2015). Theranostic applications of Lutetium-177 in radionuclide therapy. Current Radiopharmaceuticals, 9(1), 94–101. [CrossRef] 15. Kuznetsov, R.A., Bobrovskaya, K.S., Svetukhin, V.V., Fomin, A.N., Zhukov, A.V. (2019). Production of lutetium-177: Process aspects. Radioc